Literature DB >> 7657503

An analytic comparison of laparoscopic hernia repair with open "tension-free" hernioplasty.

P K Amid1, A G Shulman, I L Lichtenstein.   

Abstract

Two of the most important etiological factors in the development of primary and recurrent inguinal hernias are collagen deficiency and tension on the suture line respectively. These factors can be eliminated by the use of open "tension-free" hernioplasty, advocated by the Lichtenstein Hernia Institute since 1984. In this procedure, the entire floor of the inguinal canal is reinforced by an 8 cm x 16 cm sheet of Marlex mesh that is sutured in place to protect the floor from all future adverse mechanical and metabolic effects without the risk of displacement or folding. A new ring and shutter mechanism is also created by the procedure, which is performed under local anesthesia and requires only a few hours of in-hospital postoperative observation. Pain control following the operation involves only 2-20 tablets of 5 mg hydrocodone bitartrate, for 2-4 days. The recurrence rate of early procedures was a mere 0.1%, and has been zero for 2,500 patients treated in the past five years. In addition, there has only been one complication (a testicular atrophy) in 4,000 operations over ten years. The postoperative pain and recovery period of the "tension free" procedure compare favorably with those of laparoscopic repair, while the complication and recurrence rate and costs are significantly lower. The Lichtenstein "tension-free" method has been performed on tens of thousands of patients worldwide and these results have been duplicated and published by authors from the United States, England, Belgium, Spain, Italy and Austria.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7657503

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  9 in total

1.  Guidelines for inguinal hernia repair in everyday practice.

Authors:  J Metzger; N Lutz; I Laidlaw
Journal:  Ann R Coll Surg Engl       Date:  2001-05       Impact factor: 1.891

2.  Kugel patch method prevents the development of a femoral hernia after inguinal herniorrhaphy.

Authors:  Satoshi Nishiwada; Hirofumi Ishikawa; Yasuko Tsuji; Kota Nakamura; Tomohide Mukogawa; Masanori Matsusaka; Saiho Ko; Akihiko Watanabe
Journal:  Surg Today       Date:  2014-03-15       Impact factor: 2.549

3.  Evolution of an inguinal hernia surgery practice.

Authors:  M Mokete; J J Earnshaw
Journal:  Postgrad Med J       Date:  2001-03       Impact factor: 2.401

4.  Is a dissection balloon beneficial in totally extraperitoneal endoscopic hernioplasty (TEP)? A randomized prospective multicenter study.

Authors:  S Bringman; A Ek ; E Haglind; T Heikkinen; A Kald; F Kylberg; S Ramel; C Wallon; B Anderberg
Journal:  Surg Endosc       Date:  2001-02-27       Impact factor: 4.584

5.  Is unilateral laparoscopic TEP inguinal hernia repair a job half done? The case for bilateral repair.

Authors:  Prejesh Philips; Jagdish Chander; Vinod K Ramteke
Journal:  Surg Endosc       Date:  2010-02-05       Impact factor: 4.584

6.  Five-year outcome of laparoscopic and Lichtenstein hernioplasties.

Authors:  T Heikkinen; S Bringman; P Ohtonen; P Kunelius; K Haukipuro; A Hulkko
Journal:  Surg Endosc       Date:  2004-01-23       Impact factor: 4.584

7.  Long-term outcomes of emergency Lichtenstein hernioplasty for incarcerated inguinal hernia.

Authors:  Darin Lohsiriwat; Varut Lohsiriwat
Journal:  Surg Today       Date:  2013-01-30       Impact factor: 2.549

8.  Comparison of Kugel and Lichtenstein operations for inguinal hernia repair: results of a prospective randomized study.

Authors:  Osman Dogru; Mustafa Girgin; Nurullah Bulbuller; Ziya Cetinkaya; Erhan Aygen; Cemalettin Camci
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

9.  Laparoscopic total extraperitoneal (TEP) inguinal hernia repair under epidural anesthesia: a detailed evaluation.

Authors:  Pawanindra Lal; P Philips; K N Saxena; R K Kajla; J Chander; V K Ramteke
Journal:  Surg Endosc       Date:  2006-12-16       Impact factor: 3.453

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.